Category: Epidarex Portfolio News
Dr Keeney joins NodThera with over 20 years of pharmaceutical industry experience, including most recently at Sanofi and prior to that at Johnson & Johnson Cambridge, UK and Boston, MA, 24 September 2018. NodThera, a biotechnology company focused on the discovery and development of next…
CRESTWOOD, Ky., and WALTHAM Mass. – Apellis Pharmaceuticals Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, today announced that it has commenced its Phase 3 clinical program for APL-2 in…
PHAROAH Trial Results to-Date Show APL-2 Monotherapy Eliminated Transfusion Dependency and Improved Markers of Anemia in PNH Patients on Soliris™ CRESTWOOD, Ky., and WALTHAM Mass. – Apellis Pharmaceuticals Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through…
London, 22 August 2018 – IGEM Therapeutics (IGEM), an immuno-oncology company developing novel immunoglobulin E (IgE) antibodies to treat cancer, today announced that it has been shortlisted as a finalist in the 2018 OBN Awards in the “Best Start-up Biotech Company” category. The “Best Start-up…
CRESTWOOD, Ky., and WALTHAM, Mass., – Apellis Pharmaceuticals Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track…
CRESTWOOD, Ky. and WALTHAM, Mass. — Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, today announced that it has commenced its PEGASUS Phase 3 trial assessing the safety and…
Severely anemic patients with PNH on treatment with Soliris™ can become transfusion-free with improved hemoglobin when switched to APL-2 monotherapy. Treatment-naïve patients with PNH show clinically meaningful improvements for all hematological parameters when treated with APL-2. CRESTWOOD, Ky. and WALTHAM, Mass. — Apellis Pharmaceuticals, Inc. (Nasdaq:APLS),…
NodThera discovers and develops next generation NLRP3 inflammasome inhibitors for the treatment of diseases driven by chronic inflammation Cambridge, UK, 25 June 2018 – NodThera, a biotechnology company focused on the discovery and development of next generation NLRP3 inflammasome inhibitors for the treatment of diseases…